Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Contineum Therapeutics, Inc. (CTNM) had Return on Tangible Equity of -7.09% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-12.79M |
|
-- |
|
-- |
|
$14.93M |
|
$-14.93M |
|
$2.14M |
|
$-12.79M |
|
$-12.79M |
|
$-12.79M |
|
$-12.79M |
|
$-12.79M |
|
$-12.79M |
|
$-14.93M |
|
$-14.85M |
|
28.12M |
|
28.12M |
|
$-0.45 |
|
$-0.45 |
|
| Balance Sheet Financials | |
$184.93M |
|
$0.88M |
|
$5.92M |
|
$190.85M |
|
$6.36M |
|
-- |
|
$4.02M |
|
$10.38M |
|
$180.47M |
|
$180.47M |
|
$180.47M |
|
29.18M |
|
| Cash Flow Statement Financials | |
$-42.27M |
|
$43.74M |
|
$19.22M |
|
$21.94M |
|
$42.63M |
|
$20.69M |
|
$7.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
29.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.09% |
|
|
Return on Tangible Equity |
-7.09% |
-6.70% |
|
-7.09% |
|
$6.18 |
|
$-1.51 |
|
$-1.50 |
|